HISTORY OF DEVELOPMENT OF PROSTAGLANDIN-RELATED OPHTHALMIC SOLUTIONS
In 1981, Camras and Bito (1) demonstrated that ophthalmic administration of prostaglandin (PG)F 2α caused a decrease in the intraocular pressure (IOP). However, because PGF 2α caused initially an increase in the IOP and also induced severe local irritation, further studies were conducted to overcome these side effects. These studies led to the development and eventual clinical use of the PGF 2α -related agent, latanoprost, as the first anti-glaucoma solution in this class. Later, studies by Goh et al (2) in Japan led to the development of the docosanoid, isopropyl unoprostone (referred to unoprostone thereafter), which was approved for clinical use in Japan in 1994. Thereafter, the prostanoid, bimatoprost, became available in 1997 and another PGF 2α -related agent, travoprost, became available in 1999.
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Currently, the above four PG-related ophthalmic solutions are in clinical use in the US. The structures of these compounds are shown in Figure 1 .
STRUCTURAL FEATURES AND COMPARISON OF PG-RELATED OPHTHALMIC SOLUTIONS
The IOP is determined by the production and outflow of the aqueous humor, and as indicated in Figure 2 , humans have two aqueous humor outflow routes. The aqueous humor is produced by the ciliary body epithelial cells, passes through the pupillary region and flows towards the iridocorneal angle. The outflow tract from the iridocorneal angle through the trabecular meshwork and the canal of Schlemm to the venous circulation is called the conventional outflow route, and this is the major aqueous humor outflow tract occupying more than 90% of total outflow in normal eye. The system from the iridocorneal angle between the ciliary muscle bundles and the subscleral space is called the uveoscleral outflow route. In normal eyes, it accounts for less than 10% of the total aqueous humor outflow. The aqueous humor outflow from the conventional route changes depending on the IOP, but the efficiency of the uveoscleral outflow is unaffected by the IOP.
The widely used conventional glaucoma treatment drugs, Prostaglandin analogues as anti-glaucoma agents beta-blockers and carbonic anhydrase inhibitors, inhibit the production of the aqueous humor from the ciliary body epithelial cells and decrease the IOP. Pilocarpine increases the conventional outflow and decreases the IOP. The major mechanism of IOP reduction by the PG-related ophthalmic solutions is thought to be the promotion of the uveoscleral outflow, but some PG-related ophthalmic solutions have also been suggested to increase the conventional outflow, although the details are unknown. This review will mainly summarize the pharmacological mechanism of action of latanoprost in reducing the IOP, since much progress has been made in the research of this drug. Although the PG-related anti-glaucoma ophthalmic solutions have only few systemic adverse effects, they are known to cause local adverse effects, such as increased pigmentation of the iris, hypertrichosis of the eyelids, and cystoid macular edema. This review also summarizes the mechanisms underlying these adverse effects.
MECHANISM OF IOP REDUCTION BY LATANOPROST
Latanoprost was developed on the basis of studies by J. Stjernschantz and L. Bito, and its clinical use began in North America and Europe in 1995 (3). Its structure is similar to PGF 2α ( Fig. 1 ) and has a high PGF 2α (FP) receptor selectivity. Of the aqueous humor outflow routes indicated in Figure 2 , latanoprost has no effect on the conventional outflow but promotes the uveoscleral outflow of the aqueous humor, thereby decreasing the IOP. The promotion of the uveoscleral outflow of the aqueous humor has been attributed to (i) ciliary muscle relaxation, resulting in greater gaps between the muscle bundles, thus allowing greater outflow of the aqueous humor, and (ii) remodeling of the extracellular matrix (ECM) surrounding the ciliary muscle bundles, thus promoting the outflow of the aqueous humor through the ECM. However, a number of reports contradict the former theory. Namely, although pilocarpine can increase muscle contraction and decrease the uveoscleral outflow, it does not interfere with the IOP lowering effects when used concurrently with latanoprost, but rather has synergistic effects to decrease the IOP. Further, the latanoprost-mediated relaxation of the ciliary muscle (which has an important role in accommodation) could affect refraction, but no such changes were observed clinically (4-7) after latanoprost application. Thus, ciliary muscle relaxation effect, if present, would be mild and only a part of the mechanism of IOP reduction. We now focus on the studies investigating the remodeling of the ciliary body ECM. Tamm et al (8) studied the changes in the ciliary muscle structure caused by PGF 2α in humans and found that the smooth muscle cells lose their connection to the extracellular fibrils because of PGF 2α -induced lysis of extracellular material. That raised the possibility that PGs might affect the ECM (8) . The Weinreb group conducted in vitro experiments and reported that the PGF 2α acts on the ciliary muscle cells at the AP-1 site and increases the expression of c-FOS (9) , and that latanoprost increases the expression of the mRNA (10) and protein (11) of the ECM degrading enzyme, matrix metalloproteinase (MMP), induces an increase in the MMP release by ciliary smooth muscle cells (12) , and affects the content of collagen, a major ECM component (13) . Similar data was reported by Ocklind, both in vitro and in vivo (14) . Figure 3 shows zymography indicating the changes in the MMP activity when cultured ciliary muscle cells are treated with PG-related solutions. These data strongly suggest that latanoprost affects the ECM remodeling in the ciliary body as summarized in Table 1 . However, these changes occurred 
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in the ECM long time after latanoprost treatment and thus cannot explain the significant decrease in the IOP seen clinically 2-3 hour after ophthalmic administration. At present, it may be suggested that both the ciliary muscle relaxation and the ECM changes contribute to the promotion of the aqueous humor outflow.
MECHANISM OF IOP REDUCTION BY UNOPROSTONE
Unoprostone is 13,14-dihydro-15-keto-20-ethyl-PGF 2α -isopropyl ester developed in Japan. It became available for clinical use in 1994 in Japan, and in 2001 in North America. As indicated in Figure 1 , it has a ketone group at position 15 and has very low selectivity toward any of the known PG-receptors (15) . Furthermore, unoprostone is rapidly metabolized in the eye after ophthalmic administration (16) . Figure 4 shows the intraocular metabolism of latanoprost and unoprostone. The major pharmacologically active component in the eye is not unoprostone but rather is likely to be its metabolite(s) (Fig. 5) . However, the metabolites have PG receptor affinities that are even lower than unoprostone itself (personal communication). Therefore, it seems unlikely that the mechanism of action of this drug is through pharmacological effects on the previously reported PG receptors.
The mechanism of IOP reduction by unoprostone has been proposed to be either promotion of aqueous humor through the conventional route (17) or an increase in the uveoscleral outflow, but there is no agreement regarding this issue. As with latanoprost, unoprostone has been reported to increase the MMP activity in in vitro experiments (Fig. 6)(18) , but it remains unclear why the PG receptor affinity is extremely low even though the drug has pharmacological activity. As seen for latanoprost (19) , the intraocular unoprostone metabolite(s) can induce endogenous PGF 2α and PGE 2 ( Fig. 7)(20) , and the induction of endogenous PGs may contribute to the drug activity. However, the details of the mechanisms of IOP reduction by unoprostone remain unclear. Bimatoprost enhances the pressure-sensitive outflow pathway. There is a report of additional beneficial effects that may include an increase in the rate of flow in the uveoscleral outflow pathway and lowering of the episcleral venous pressure (21) , but the detailed mechanisms are unknown.
MECHANISM OF IOP REDUCTION BY BIMATOPROST

MECHANISM OF IOP REDUCTION BY TRAVOPROST
Travoprost (AL-6221), which is isopropyl (Z)-7-[(1R, 2R, 3R, 5S)-3, 5-dihydroxy-2-[(1E, 3R)-3-hydroxy-4-[(α, α, α-trifluoro-m-tolyl)oxy]-1-butenyl]cyclopentyl]-5-heptenoate,
is the isopropyl ester of a single enantiomer of the selective FP prostaglandin receptor agonist, fluprostenol. It is a PG analogue with a high FP receptor selectivity (22) and promotes aqueous humor outflow via the uveoscleral route (23) . Its ability to decrease the IOP seem to be better than timolol and equivalent to latanoprost. Only a few adverse effects are known. However, a detailed mechanism of reduction in the IOP has not been elucidated.
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ADVERSE EFFECTS CAUSED BY PG-RELATED AGENTS
Increased pigmentation of the iris
A frequently seen adverse effect of the currently available PG-related solutions is the increased pigmentation of the iris (24) (25) (26) (27) . Figure 8 shows representative iridial pigmentation induced by either latanoprost or unoprostone. The mechanism of pigment deposition by latanoprost involves increase of the tyrosinase activity without inducing cell division in the iris or dermal melanocytes, and thus causing melanin increase ( Fig. 9 ) (27) (28) (29) (30) (31) (32) (33) (34) . Our results showed that in addition to the increased melanogenesis by increased tyrosinase activity, latanoprost but also causes an increased pigmentation of melanin (28, 29) . We and others reported an increase in eumelanin/ pheomelanin ratio in the latanoprost-administered animal models (28, 29, 35) . We have observed the same effect also for unoprostone, but with a lower incidence of the increased pigmentation compared to latanoprost (28) . Other PG-related agents have also been reported to increase the pigmentation of the iris, but the details remain unclear. The increased melanin is not released outside of the cell, and there is no increase in the melanin deposition in the iridocorneal angle and other ocular tissues. IOP elevation or a malignant transformation have not been observed. Thus, at this point, this complication remains only an esthetic problem.
Hair-growth
Recently, latanoprost has been recognized as a drug capable of regularly inducing hypertrichosis involving eyelashes, adjacent adnexal hair, and vellus hair of the skin (36, 37) . Hair growth cycle involves the anagen, catagen, and telogen, and latanoprost has been suggested to cause longer anagen follicle phase than normal compared to the telogen follicle phase (38) . This effect is said to be reversible, but this has not been confirmed. Hair growth involves many genes and growth factors that affect the hair growth and hair cycling, and how latanoprost is implicated remains unclear.
Recurrence of uveitis
There have been reports of uveitis recurring in patients with a history of uveitis treated with latanoprost. The mechanism is not well understood. Latanoprost has been reported to induce PGE 2 , an PG involved in inflammation (20) , which may be involved in this phenomenon.
Cystoid macular edema (CME)
CME is an important local adverse effect seen in PG-related solutions because it affects vision. CME is thought to be more frequent in patients with a history of intraocular surgery, where the blood/aqueous humor barrier has been affected. Figure  10 shows a representative case with cystoid macular edema induced by latanoprost ophthalmic solution. The details of the pathogenetic mechanism is unclear, but the involvement of endogenous PGE 2 has been proposed, because latanoprost induces endogenous PGE 2 (20) , and because concurrent administration of non-steroidal anti-inflammatory drugs with 
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Prostaglandin analogues as anti-glaucoma agents latanoprost after cataract surgery suppresses the development of CME (39) . This adverse effect is rare in patients with no history of breakdown of the blood/aqueous humor barrier (40) , and it is therefore considered that the administration of latanoprost should be performed with caution in patients with a history of barrier breakdown. CME has not been reported with unoprostone, probably because of the rapid intraocular metabolism of unoprostone and its conversion into inactive compound(s) (16) . There are no data concerning the development of this adverse effect in the other two PG-related solutions because of the short time elapsed after their approval.
CONCLUSION
The pharmacological action of the PG-related agents is predominantly to promote the uveoscleral outflow of aqueous humor. Their introduction has increased the interest in the uveoscleral outflow, which previously had not received much attention. At the same time, many questions remain unanswered. It is widely recognized that uveoscleral outflow in the physiological state accounts for only 10% of the aqueous humor outflow, and it remains unclear how the PG-related solutions can then cause a remarkable IOP decrease. The conventional route is directly in contact with the veins and thus is affected by the venous pressure, while the uveoscleral route is not directly connected to the vasculature and is not affected by the venous pressure. Thus, the uveoscleral route may reduce the IOP more effectively than the conventional route, because its use is not limited by the effects of the venous pressure.
Therefore, the approach involving the uveoscleral outflow has attracted new attention in the treatment of glaucoma. 
